High-performance liquid chromatographic determination of doxazosin in human plasma for bioequivalence study of controlled release doxazosin tablets

Biomedical Chromatography

Volumn 20, Issue 11, 2006, Pages 1172-1177

  Kim, Young Jae ^a   Lee, Yoonjin ^a   Kang, Myung Joo ^a   Huh, Jin Seo ^a   Yoon, Mikyeong ^a   Lee, Jaehwi ^a   Choi, Young Wook ^a  

^a Chung Ang University   (South Korea)

Author keywords

Bioequivalence; Controlled release; Doxazosin; HPLC; Human plasma

Indexed keywords

PLASMA (HUMAN);

BIOEQUIVALENCE; BIOEQUIVALENCE STUDY; CHROMATOGRAPHIC DETERMINATION; CONTROLLED RELEASE; DOXAZOSIN; HPLC; HUMAN PLASMAS; INTERNAL STANDARDS; PERFORMANCE; PLASMA MATRIX;

HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

ACETIC ACID ETHYL ESTER; DOXAZOSIN MESYLATE; PERCHLORIC ACID; PROPRANOLOL; SULFONIC ACID DERIVATIVE;

ACCURACY; ARTICLE; BIOEQUIVALENCE; CALIBRATION; CONCENTRATION RESPONSE; CONTROLLED RELEASE FORMULATION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ISOLATION; DRUG STABILITY; DRUG STRUCTURE; FLOW RATE; FLUORESCENCE ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; LIQUID LIQUID EXTRACTION; MALE; NORMAL HUMAN; PLASMA; QUANTITATIVE ANALYSIS; SEPARATION TECHNIQUE; VALIDATION PROCESS; VOLUNTEER;

EID: 33751105866     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.666     Document Type: Article

References (11)

1. Andersson PE, Johansson J, Berne C and Lithell H. Effects of selective alfa 1 and beta 1-adrenoreceptor blockade on lipoprotein and carbohydrate metabolism in hypertensive subjects, with special emphasis on insulin sensitivity. Journal of Human Hypertension 1994; 8: 219.
2. Black HR, Sollins JS and Garofalo JL. The addition of doxazosin to the therapeutic regimen of hypertensive patients inadequately controlled with other antihypertensive medications: a randomized, placebo-controlled study. American Heart Journal 2000; 13: 468.
3. Brown MJ and Dickerson JE. Alpha-blockade and calcium antagonism: an effective and well-tolerated combination for the treatment of resistant hypertension. Journal of Hypertension 1991; 9: S362.
4. Cho HY, Kim SJ, Shim YS, Lim DK, Oh IJ, Moon JD and Lee YB. Bioequivalence of Cardil tablet to Cardura tablet (doxazosin 2 mg). Journal of Korea Pharmaceutical Sciences 2000; 30: 61.
5. Chung M, Vashi V, Puente J, Sweeney M and Meredith P. Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation. British Journal of Clinical Pharmacology 1999; 48: 678.
6. Englert RG and Barlage U. The addition of doxazosin to the treatment regimen of patients with hypertension not adequately controlled by beta-blockers. American Heart Journal 1991; 121: 311.
7. Fawzy A, Vashi V, Chung M, Dias N and Gaffney M. Correlation of maximal urinary flow rate and plasma doxazosin concentrations in the treatment of benign prostatic hyperplasia. Multicenter Study Group. Urology 1999; 53: 329.
8. Fulton B, Wagstaff A and Sorkin E. Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. Drugs 1995; 49: 295.
9. Jackman GP, Colagrande F and Louis WJ. Validation of a solid-phase extraction high-performance liquid chromatographic assay for doxazosin. Journal of Chromatography. Biomedical Applications 1991; 566: 234.
10. Os I and Stokke HP. Effects of doxazosin in the gastrointestinal therapeutic system formulation versus doxazosin standard and placebo in mild-to-moderate hypertension. Doxazosin Investigators' Study Group. Journal of Cardiovascular Pharmacology 1999; 33: 791.
11. Sripalakit P, Nermhom P and Saraphanchotiwitthaya A. Improvement of doxazosin determination in human plasma using high-performance liquid chromatography with fluorescence detection. Journal of Chromatographic Science 2005; 43: 63.